Jump to main content
Jump to site search

Issue 7, 2019
Previous Article Next Article

Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy

Author affiliations

Abstract

The combination of gene therapy and immunotherapy has the potential to systemically promote anti-tumor effects while reducing adverse reactions. Small interfering RNA (siRNA) has generated great interest in biology, engineering and medicine, especially for cancer treatment due to its ability to knock down genes of interest. Nanomaterials play significant roles in the design of delivery systems of siRNA, and nanomaterial-mediated siRNA delivery in cancer immunotherapy is one of the most important directions for future clinical cancer treatment. Here, we review the recent advances in nanomaterial mediated targeted delivery of siRNA to dendritic cells (DCs), tumor-associated macrophages (TAMs), immune checkpoint inhibitors, B lymphocytes, natural killer cells (NKs), and immunosuppressive cytokines. Fundamental challenges in nucleic acid delivery enabled by bio-barriers, its promising solution strategies and future directions are also reviewed.

Graphical abstract: Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy

Back to tab navigation

Publication details

The article was received on 10 Feb 2019, accepted on 02 Apr 2019 and first published on 13 Apr 2019


Article type: Review Article
DOI: 10.1039/C9BM00214F
Biomater. Sci., 2019,7, 2640-2651

  •   Request permissions

    Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy

    Y. Mei, R. Wang, W. Jiang, Y. Bo, T. Zhang, J. Yu, M. Cheng, Y. Wu, J. Cheng and W. Ma, Biomater. Sci., 2019, 7, 2640
    DOI: 10.1039/C9BM00214F

Search articles by author

Spotlight

Advertisements